A Single LSD-Derived Dose Shows Phase 3 Promise Against Major Depression

Definium Therapeutics reported that a single dose of DT120 significantly reduced major-depression symptoms six weeks after treatment in a Phase 3 trial. The findings could advance psychedelic medicine toward regulatory review, but full peer-reviewed data, long-term safety and independent confirmation remain essential.